ArticleCurrent treatment options in rheumatology2017
Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.
Article in Current treatment options in rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.Clinical and experimental immunology · 2026Review
- Criteria for Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024Review
- Therapeutic Potential of Bioactive Compounds from Edible Mushrooms to Attenuate SARS-CoV-2 Infection and Some Complications of Coronavirus Disease (COVID-19).Journal of fungi (Basel, Switzerland) · 2023Review
- Assessment of some Physiological Biomarkers in COVID-19 Patients in Thi-Qar, Iraq.Archives of Razi Institute · 2022Article
- Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption.Journal of anesthesia, analgesia and critical care · 2022Review
- Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorbInternational journal of molecular sciences · 2021Article
- Review
- Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19.Immunity, inflammation and disease · 2021Review
- SARS-CoV-2 infection represents a high risk for the elderly: analysis of pathogenesis.Archives of virology · 2021Review
- Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.Pediatric rheumatology online journal · 2021Review
- The Novel Coronavirus and Inflammation.Advances in experimental medicine and biology · 2021Review
- Adsorption therapy in critically ill with septic shock and acute kidney injury: a retrospective and prospective cohort study.Annals of intensive care · 2020Article
- Cyclosporine: an old weapon in the fight against coronaviruses.The European respiratory journal · 2020Article
- Management principles in patients with COVID-19: perspectives from a growing global experience with emphasis on cardiovascular surveillance.Open heart · 2020Review
- Article
- Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity.International journal of molecular sciences · 2020Review
- Association between ABO blood groups and susceptibility to COVID-19: profile of age and gender in Iraqi patients.The Egyptian journal of medical human genetics · 2020Article
- Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.Frontiers in immunology · 2020Article
- A human immune dysregulation syndrome characterized by severe hyperinflammation with a homozygous nonsense Roquin-1 mutation.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cytokine storm syndromes require rapid diagnosis and treatment to limit the morbidity and mortality caused by the hyperinflammatory state that characterizes these devastating conditions. Herein, we discuss the current knowledge that guides our therapeutic decision-making and personalization of treatment for patients with cytokine storm syndromes. Firstly, ICU-level supportive care is often required to stabilize patients with fulminant disease while additional diagnostic evaluations proceed to determine the underlying cause of cytokine storm. Pharmacologic interventions should be focused on removing the inciting trigger of inflammation and initiation of an individualized immunosuppressive regimen when immune activation is central to the underlying disease pathophysiology. Monitoring for a clinical response is required to ensure that changes in the therapeutic regimen can be made as clinically warranted. Escalation of immunosuppression may be required if patients respond poorly to the initial therapeutic interventions, while a slow wean of immunosuppression in patients who improve can limit medication-related toxicities. In certain scenarios, a decision must be made whether an individual patient requires hematopoietic cell transplantation to prevent recurrence of disease. Despite these interventions, significant morbidity and mortality remains for cytokine storm patients. Therefore, we use this review to propose a clinical schema to guide current and future attempts to design rational therapeutic interventions for patients suffering from these devastating conditions, which we believe speeds the diagnosis of disease, limits medication-related toxicities, and improves clinical outcomes by targeting the heterogeneous and dynamic mechanisms driving disease in each individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.